Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
NUVA.US
id: 607, Created by Stan Vick Chase, Scout
Join NuVasive (NUVA) & Globus Medical (GMED) M&A Case to Fight Losses
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
How it works?
- We find Attorney for the Case
- Attorney files case on behalf of Investors
- You get updates and receive payout in case of success
Would it cost me anything?
- No, you do not pay anything out of your pocket neither to us, nor to Attorney
- Attorneys get % fee in case of success
- Platform charges service fee from Attorneys
What are the chances for success?
Every Case is unique, but statistically, 47% of Cases end up with a settlement.
Please see below recent successful cases:
- #NuVasive's BoD unanimously approved the M&A deal with #GlobusMedical.
- $NUVA #shareholders will receive 0.75 of $GMED A stock.
- #Investors suspect that the pricing terms of the $NUVA & GMED #M&A deal are unfair.
On February 9, 2023, NuVasive (NASDAQ: NUVA), the leader in spine technology innovation, and Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, announced they have entered into a definitive agreement to combine in an all-stock transaction.
Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, NuVasive (NUVA) shareholders will receive 0.75 of a share of Globus Medical Class A common stock for each share of NuVasive common stock owned at the closing of the transaction.
Based on this exchange ratio, the implied share price for NuVasive (NUVA) would be $57.72, an equity value of $3.1 billion, based on Globus Medical's closing share price on February 8. Following the close of the transaction, NuVasive shareholders will own approximately 28% of the combined company, and Globus Medical shareholders will own approximately 72%, on a fully diluted basis.
Investors may have reasons to suspect that the pricing terms of the M&A transaction are unfair and that the Company BoD breached fiduciary duties to shareholders.
Alleged Offence
Mismanagement,
Financial Misrepresentation,
Failure to Disclose,
Malpractice,
Negligence,
Breach of Fiduciary duty,
Omissions
Suspected Party
Directors,
Management,
Shareholder,
Investment Bank,
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
09 March 2023